Apotex Health Toronto IPO Overview
Apotex Health (TSX:APTX) debuted on the Toronto Stock Exchange with shares opening at $28, representing a 17% premium to the $24 per share IPO price. The company priced an upsized offering of 54.17 million common shares at $24 each, raising roughly C$1.3 billion in gross proceeds. This amount makes the transaction the largest initial public offering on the TSX in the past five years and the biggest since Definity Financial raised about C$1.6 billion in 2021. Only seven IPOs have been listed on the exchange since 2022, underscoring the significance of the deal.
The offering provides investors exposure to a Canadian health‑care firm within an index that is otherwise dominated by financial, oil and mining stocks. Prior to the public offering, the company was owned by New York‑based private‑equity firm SK Capital Partners, which is exiting its stake as part of the IPO.
Management outlined growth plans that include launching more than one hundred additional generic pharmaceutical products, expanding operations in Mexico and the Middle East, and focusing on high‑margin drug lines. Founded by Barry Sherman in 1974, Apotex now manufactures over 800 pharmaceutical and consumer‑health products, operates in approximately 70 countries, and employs more than 6,000 people worldwide.
Key Financial Metrics
- Offering size: 54.17 million shares
- IPO price: $24 per share
- Gross proceeds: ~C$1.3 billion
- Opening price: $28 per share (17% above IPO price)
- Largest TSX IPO in five years; fourth‑largest since 2021
Strategic Outlook
Apotex intends to leverage the capital raised to broaden its generic portfolio, target new geographic markets, and enhance profitability through high‑margin products.